EPISODE · Oct 15, 2021 · 1H 17M
Episode 063 - The Life of a Psychedelic Legend & The Shulgin Scale w/ Alexander 'Sasha' Shulgin
from Midnight, On Earth
In this episode, Brynn Anderson and I take a peek into the psychedelic life of master chemist Alexander 'Sasha' Shulgin, creator of over 250 psychedelic compounds such as 2C-I and 2C-B...We listen to some incredible interviews from both 1996 and 2013, just prior to Sasha's death. We discuss how his many psychedelic compounds have influenced humanity ,as Shulgin was on a quest to be a toolmaker for psychedelic research. Listen In!Alexander Shulgin Bio:Dr. Alexander "Sasha" Theodore Shulgin or "Shura" was an American chemist, pharmacologist, psychopharmacologist, and author.Over the span of 50 years, he created more new psychedelic drugs than any other known person to date - nearly 250 by his own accounts.Shulgin also rediscovered the drug MDMA and established its use as a tool in clinical psychedelic therapy for a short time. He has written two books detailing his endeavors, PiHKAL and TiHKAL, and also contributed numerous highly appraised chemical assays and studies throughout the years.Shulgin is best known for synthesizing the psychoactive drugs 2C-T-7, 2C-B, 2C-E, 2C-I, DOM and hundreds of others. Due in part to Shulgin's extensive work in the field of psychedelic research and the rational drug design of psychedelic drugs, he has since been dubbed the "godfather of psychedelics". Prior to his 2010 health issues, Shulgin had been working on a series of N- allylated tryptamines including 5-MeO-DALT and 5-MeO-MALT On April 17, 2014, Ann Shulgin reported on Facebook that her husband had developed liver cancer, and in a May 31 update on Facebook she said that, although appearing frail, he seemed to be experiencing his last moments in peace and without pain. On June 2, 2014, Shulgin died at home in bed surrounded by family, fifteen days before his 89th birthday Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
In this episode, Brynn Anderson and I take a peek into the psychedelic life of master chemist Alexander 'Sasha' Shulgin, creator of over 250 psychedelic compounds such as 2C-I and 2C-B...We listen to some incredible interviews from both 1996 and 2013, just prior to Sasha's death. We discuss how his many psychedelic compounds have influenced humanity ,as Shulgin was on a quest to be a toolmaker for psychedelic research. Listen In!Alexander Shulgin Bio:Dr. Alexander "Sasha" Theodore Shulgin or "Shura" was an American chemist, pharmacologist, psychopharmacologist, and author.Over the span of 50 years, he created more new psychedelic drugs than any other known person to date - nearly 250 by his own accounts.Shulgin also rediscovered the drug MDMA and established its use as a tool in clinical psychedelic therapy for a short time. He has written two books detailing his endeavors, PiHKAL and TiHKAL, and also contributed numerous highly appraised chemical assays and studies throughout the years.Shulgin is best known for synthesizing the psychoactive drugs 2C-T-7, 2C-B, 2C-E, 2C-I, DOM and hundreds of others. Due in part to Shulgin's extensive work in the field of psychedelic research and the rational drug design of psychedelic drugs, he has since been dubbed the "godfather of psychedelics". Prior to his 2010 health issues, Shulgin had been working on a series of N- allylated tryptamines including 5-MeO-DALT and 5-MeO-MALT On April 17, 2014, Ann Shulgin reported on Facebook that her husband had developed liver cancer, and in a May 31 update on Facebook she said that, although appearing frail, he seemed to be experiencing his last moments in peace and without pain. On June 2, 2014, Shulgin died at home in bed surrounded by family, fifteen days before his 89th birthday Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Episode 063 - The Life of a Psychedelic Legend & The Shulgin Scale w/ Alexander 'Sasha' Shulgin
No transcript for this episode yet
Similar Episodes
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m
Sep 20, 2024 ·57m
Aug 7, 2024 ·16m